Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 363595, 6 pages
http://dx.doi.org/10.1100/2012/363595
Clinical Study

Long-Term Prospective Study of the Influence of Estrone Levels on Events in Postmenopausal Women with or at High Risk for Coronary Artery Disease

1Heart Institute (InCor), University of São Paulo Medical School, 05403-000 São Paulo, SP, Brazil
2School of Public Health, University of São Paulo, 01246-904 São Paulo, SP, Brazil

Received 6 February 2012; Accepted 29 February 2012

Academic Editors: Y. Murakawa, B. Pitt, and C. Spaulding

Copyright © 2012 Antonio de Padua Mansur et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Xing, S. Nozell, Y. F. Chen, F. Hage, and S. Oparil, “Estrogen and mechanisms of vascular protection,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 3, pp. 289–295, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Nilsson, S. Mäkelä, E. Treuter et al., “Mechanisms of estrogen action,” Physiological Reviews, vol. 81, no. 4, pp. 1535–1565, 2001. View at Google Scholar · View at Scopus
  3. E. Murphy and C. Steenbergen, “Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury,” Cardiovascular Research, vol. 75, no. 3, pp. 478–486, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Hulley, D. Grady, T. Bush et al., “Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women,” Journal of the American Medical Association, vol. 280, no. 7, pp. 605–613, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. Writing Group for the Women's Health Initiative Investigators, “Risks and benefits of estrogen plus progestin in healthy postmenopausal women,” Journal of the American Medical Association, vol. 288, pp. 321–333, 2002. View at Google Scholar
  6. S. M. Harman, E. Vittinghoff, E. A. Brinton et al., “Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes,” American Journal of Medicine, vol. 124, no. 3, pp. 199–205, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. J. Gruber, W. Tschugguel, C. Schneeberger, and J. C. Huber, “Mechanisms of disease: Production and actions of estrogens,” New England Journal of Medicine, vol. 346, no. 5, pp. 340–352, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Lukanova, E. Lundin, A. Zeleniuch-Jacquotte et al., “Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women,” European Journal of Endocrinology, vol. 150, no. 2, pp. 161–171, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. T. C. B. F. Silva, E. Barrett-Connor, J. A. F. Ramires, and A. P. Mansur, “Obesity, estrone, and coronary artery disease in postmenopausal women,” Maturitas, vol. 59, no. 3, pp. 242–248, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Mosca, E. Barrett-Connor, N. K. Wenger et al., “Design and methods of the Raloxifene Use for The Heart (RUTH) study,” American Journal of Cardiology, vol. 88, no. 4, pp. 392–395, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. American Diabetes Association, “Diagnosis and classification of diabetes mellitus 2006,” Diabetes Care, vol. 29, no. Suppl S), pp. S43–S48, 2006. View at Google Scholar
  12. “The Seventh Report of the Joint National Committee on Prevention, Detection, evaluation and treatment of high blood pressure,” Journal of the American Medical Association, vol. 289, pp. 2560–2572, 2003.
  13. “III Diretrizes Brasileiras Sobre Dislipidemias e Diretriz de Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia,” Arquivos Brasileiros de Cardiologia, vol. 77, pp. 4–8, 2001.
  14. World Health Organization, Guidelines for the conduct of the tobacco smoking surveys of the general population: report of a meeting, WHO, Geneva, Switzerland, 1992.
  15. Obesity: Preventing and managing the global epidemic. Report of a WHO Consultation, Technical Report Series, no. 894, World Health Organization, Geneva, Switzerland, 2000.
  16. J. A. Cauley, J. P. Gutai, N. W. Glynn, M. Paternostro-Bayles, E. Cottington, and L. H. Kuller, “Serum estrone concentrations and coronary artery disease in postmenopausal women,” Arteriosclerosis and Thrombosis, vol. 14, no. 1, pp. 14–18, 1994. View at Google Scholar · View at Scopus
  17. E. Barrett-Connor and D. Goodman-Gruen, “Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women,” British Medical Journal, vol. 311, no. 7014, pp. 1193–1196, 1995. View at Google Scholar · View at Scopus
  18. K. M. Rexrode, J. E. Manson, I. M. Lee et al., “Sex hormone levels and risk of cardiovascular events in postmenopausal women,” Circulation, vol. 108, no. 14, pp. 1688–1693, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Chen, A. Zeleniuch-Jacquotte, A. A. Arslan et al., “Endogenous hormones and coronary heart disease in postmenopausal women,” Atherosclerosis, vol. 216, no. 2, pp. 414–419, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. G. G. J. M. Kuiper, B. Carlsson, K. Grandien et al., “Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors and α and β,” Endocrinology, vol. 138, no. 3, pp. 863–870, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. S. M. Grundy, B. Hansen, S. C. Smith, J. I. Cleeman, and R. A. Kahn, “Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management.,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 2, pp. e19–e24, 2004. View at Google Scholar · View at Scopus
  22. R. H. Knopp, X. Zhu, and B. Bonet, “Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women,” Atherosclerosis, vol. 110, pp. S83–S91, 1994. View at Publisher · View at Google Scholar · View at Scopus
  23. E. L. Ding, Y. Song, V. S. Malik, and S. Liu, “Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis,” Journal of the American Medical Association, vol. 295, no. 11, pp. 1288–1299, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. I. Lambrinoudaki, G. Christodoulakos, D. Rizos et al., “Endogenous sex hormones and risk factors atherosclerosis in healthy Greek postmenopausal women,” European Journal of Endocrinology, vol. 154, no. 6, pp. 907–916, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Hsia, J. D. Otvos, J. E. Rossouw et al., “Lipoprotein particle concentrations may explain the absence of coronary protection in the women’s health initiative hormone trials,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, pp. 1666–1671, 2008. View at Google Scholar
  26. C. Walton, I. F. Godsland, A. J. Proudler, V. Wynn, and J. C. Stevenson, “The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women,” European Journal of Clinical Investigation, vol. 23, no. 8, pp. 466–473, 1993. View at Google Scholar · View at Scopus